Life Sciences

Life Sciences

Novel therapeutics for MLD – Two complementary approaches for the treatment of metachromatic leukodystrophy


Ref.-Nr. 4683/4783

Metachromatic leukodystrophy (MLD) is a genetic lysosomal accumulation disease caused by the deficiency of the enzymatic activity of arylsulfatase A (ASA). This enzyme hydrolyzes 3-O-sulfogalactosyl ceramide (sulfatide) to galactosylceramide and sulfate. Sulfatide is a sphingolipid of the myelin sheath of axons and thus important for nerve cell function. However, impaired lysosomal degradation of sulfatide by a reduction or loss of ASA activity leads to an accumulation of this sphingolipid, which results in progressive demyelination. Consequently, the patients show increasing neurological deficits and eventually die.

Keywords: MLD, Metachromatische Leukodystrophie, Arylsulfatase, ASA, Seltene Erkrankungen, Myelin, Enzymersatztherapie, Epicoccolid, metachromatic leukodystrophy, aryl sulfatase, orphan disease, neurodegenerative, myelin, enzyme replacement therapy, enzyme compensation therapy 

The inventors have developed two novel and complementary approaches for the treatment of MLD: The first approach is based on the natural products Epicoccolid B and Epipyrone, which are derived from the mold fungus Epicoccum nigrum. These compounds inhibit the cerebroside-sulfotransferase, which is an enzyme that generates sulfatide. Thereby, the sulfatide concentration is lowered.

In addition (second approach) the researchers have exchanged certain amino acids of human ASA resulting in a much higher enzymatic activity. Previous clinical studies have demonstrated the feasibility of enzyme compensation therapy for treating MLD. However, it became clear that large amounts of enzyme need to be administered thereby potentially causing significant side-effects. These problems are overcome by the present approach.

Commercial Opportunities

The aforementioned compounds as well as the mutated enzyme are offered for licensing.

Competitive Advantages

  • Novel and complementary approach for treating MLD
  • Demonstrated proof of concept

Current Status

The researcher have generated mouse models for MLD and have validated efficacy of their therapeutics. European patent priority applications have been field for both approaches.

Relevant Publications

Schuster, T., et al. (2017) Potential of surfactant-coated nanoparticles to improve brain delivery of arylsulfatase A. J Control Release, S0168-3659(17)30079-2.

Doerr, J., et al. (2015) Arylsulfatase A overexpressing human iPSC-derived neural cells reduce CNS sulfatide storage in a mouse model of metachromatic leukodystrophy. Mol Ther 23:1519-31.

bitte Kontaktieren Sie mich zu diesem angebot.

Dr. Jürgen Walkenhorst
+49.208 94105-25

Dr. Jürgen Walkenhorst

Dieses Angebot


PROvendis GmbH · Schloßstr. 11 – 15
D – 45468 Mülheim an der Ruhr
T +49 (0)208 94105-0 ·